SCHEMBL3018098

SCHEMBL3018098

Cc1cc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.39
LIPE Q05469 2/20 0.39
CHRM4 P08173 1/20 0.36
AVPR1B P47901 1/20 0.36
KIT P10721 1/20 0.35
HTR2A P28223 1/20 0.35
EPHX2 P34913 3/20 0.35
DNM1L O00429 2/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
GBA1 P04062 1/20 0.34
EPHX1 P07099 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006198 0.92 LIPE (0.38) LIPECHRM4AVPR1BKITHTR2A
SCHEMBL3016319 0.90 LIPE (0.40) FFAR4LIPECHRM4AVPR1BKIT
SCHEMBL3015515 0.88 GBA1 (0.42) DNM1LGBA1
SCHEMBL3014869 0.88 LIPE (0.40) FFAR4LIPECHRM4AVPR1BKIT
SCHEMBL3016941 0.88 LIPE (0.44) LIPECHRM4AVPR1BHTR2AEPHX2
SCHEMBL3007065 0.87 SMN1; SMN2 (0.39) HTR2ADNM1LGBA1
SCHEMBL3011689 0.87 LIPE (0.37) FFAR4LIPECHRM4AVPR1BKIT
SCHEMBL3019380 0.86 LIPE (0.38) LIPECHRM4AVPR1BKITHTR2A
SCHEMBL3008424 0.86 LIPE (0.37) LIPECHRM4AVPR1BKITHTR2A
SCHEMBL3017218 0.86 HDAC3 (0.47) FFAR4EPHX2GBA1EPHX1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FFAR4 2549/4885LIPE 2030/4885CHRM4 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.